CRN04894 for active Cushing’s syndrome—safety and drug levels
Treatments studied
Part of Brain & nervous system, Cancer, Hormones & metabolism clinical trials.
This early-phase study tests how safe CRN04894 is and what drug levels it reaches in the body in people with “active” ACTH-dependent Cushing’s syndrome. You may be considered if your condition is currently active (or became active very recently) and you meet specific medication and imaging rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older, and can join as a male or female
- Your Cushing’s syndrome is ACTH-dependent and currently active (or became active within 10 days)
- If you’re taking certain Cushing’s medicines, you must stop them for a required washout time (about 5–14 days depending on the drug)
- You cannot be pregnant or breastfeeding
- You do not have a prior surgery that removed both adrenal glands (bilateral adrenalectomy)
- You do not have certain brain MRI findings near the optic nerve or have other listed health issues (like known cancer)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well a desmopressin stimulation test works to diagnose ACTH-dependent Cushing syndrome. It compares results from people with possible or recurrent Cushing syndrome and healthy volunteers.
This study checks long-term health in people who were treated successfully for Cushing disease when they were under 21. It also collects information from family members to study genetic links to pituitary tumors.
This Phase 2 study tests seliciclib (also called R-roscovitine) in people with Cushing disease caused by a pituitary tumor and ongoing high cortisol levels. It may help reduce excess cortisol production in those whose Cushing disease has not fully gone away or has come back after standard treatment.
This Phase 2 trial tests fimepinostat (a targeted cancer-style drug) to help control Cushing disease caused by a pituitary tumor. It’s mainly for adults whose Cushing is confirmed to come from the pituitary and who meet safety and medication-washout rules.
This study looks at how Cushing’s syndrome affects people before treatment and what changes after treatment. It may help researchers understand what to expect and improve care for adults with newly diagnosed Cushing’s syndrome.
This trial tests if a drug called Metyrapone can lower heart risks in people who have adrenal nodules (noncancerous growths on the adrenal glands) and a mild form of Cushing's syndrome that doesn't cause obvious physical signs. You'll be given the drug and monitored to see if it helps control blood pressure and other heart risk factors.
Hear when a new Cushing Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.